These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 23639313)
1. Is India ready to lead the battle for fair access to medicines? Lancet Oncology Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313 [No Abstract] [Full Text] [Related]
2. Taking TRIPS to India--Novartis, patent law, and access to medicines. Mueller JM N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473 [No Abstract] [Full Text] [Related]
3. Drugmakers struggle with Indian patents. Cancer Discov; 2012 Dec; 2(12):OF5. PubMed ID: 23230206 [TBL] [Abstract][Full Text] [Related]
4. Engineered in India--patent law 2.0. Kapczynski A N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973 [No Abstract] [Full Text] [Related]
5. Final hearings begin in epic legal battle over Novartis drug in India. Mudur G BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008 [No Abstract] [Full Text] [Related]
6. [Novartis should discontinue its patent case in India!]. PehrOlov P Lakartidningen; 2007 Feb 14-20; 104(7):524. PubMed ID: 17375688 [No Abstract] [Full Text] [Related]
7. New NICE criteria for drug access. Fricker J Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973 [No Abstract] [Full Text] [Related]
8. The global impact of Indian generics on access to health. Ravinetto RM; Dorlo TP; Caudron JM; Prashanth NS Indian J Med Ethics; 2013; 10(2):118-20. PubMed ID: 23697493 [No Abstract] [Full Text] [Related]
9. Drug patent protection: how long is long enough? Sibbald B CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146 [No Abstract] [Full Text] [Related]
10. Pfizer to make palbociclib temporarily free on NHS. Burki TK Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556 [No Abstract] [Full Text] [Related]
11. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects. Bird RC J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067 [TBL] [Abstract][Full Text] [Related]
12. Patent dispute: Delhi High Court gives a boost to access to affordable medicines. Menghaney L Indian J Med Ethics; 2010; 7(2):97-100. PubMed ID: 20432882 [TBL] [Abstract][Full Text] [Related]
13. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says. Cohen D BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846 [No Abstract] [Full Text] [Related]
14. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
15. India's rejection of Novartis's patent is but a small step in the right direction. Bhaumik S BMJ; 2013 Apr; 346():f2412. PubMed ID: 23596223 [No Abstract] [Full Text] [Related]
16. Indian patients go to court over cancer drug. Murdur G BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889 [No Abstract] [Full Text] [Related]
19. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. Lybecker KM; Fowler E J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068 [TBL] [Abstract][Full Text] [Related]
20. Access to drugs: the case of Abbott in Thailand. Cawthorne P; Ford N; Wilson D; Kijtiwatchakul K; Purahong V; Tianudom N; Nacapew S Lancet Infect Dis; 2007 Jun; 7(6):373-4. PubMed ID: 17521589 [No Abstract] [Full Text] [Related] [Next] [New Search]